Cargando...
SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
Objective A multicenter, double-masked, randomized, placebo-controlled, phase two trial of 88 patients with active, moderate-to-severe Graves’ orbitopathy (GO) has demonstrated a significant and rapid response to teprotumumab, an insulin-like growth factor 1 receptor inhibitory monoclonal antibody,...
Gardado en:
| Publicado en: | J Endocr Soc |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Endocrine Society
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6552477/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-554 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|